Roche Applied Science is looking into cutting-edge solutions (technologies, reagents and instruments) to support the biomedical science community.
Roche Applied Science’s priorities include developing new and more powerful DNA microarrays [NimbleGen] , real time cell analyzers [Xcelligence] for cell culture assays and enhancing the flexibility and efficiency of the ultrafast sequencing technology [Genome FLX] for the research market.
The business area has also stepped up to contribute to the global Roche Personalised Healthcare Strategy by developing tests with potential diagnostic applications or assay systems that may facilitate drug development, particularly in oncology and inflammatory diseases.